Specialty-matching statutes for payers in peer-to-peer medical necessity reviews provide a documented legal lever where they apply, but they do not reach most commercially insured patients. Self-funded employer plans, which cover approximately 60% of commercially insured Americans, fall under the Employee Retirement Income Security Act of 1974. ERISA preempts state insurance mandates, including the utilization review statutes that require specialty-matched peer reviewers.
A provider in Texas, New Jersey, or Connecticut cannot invoke the state’s specialty-matching statute against a self-funded employer plan. State insurance departments have no jurisdiction over those plans. That gap is built into the federal statutory framework and applies across every operating market regardless of how strong the applicable state law is.
What ERISA Provides
ERISA is not a complete dead end. Section 502(a) allows providers to sue to recover benefits wrongfully denied under the plan document. Plans must maintain internal claims and appeals processes, and the Affordable Care Act added the right to independent external review for adverse benefit determinations.
Federal courts generally apply an abuse-of-discretion standard when the plan document grants the administrator discretionary authority, which most do. Under that standard, a denial does not need to be correct. It needs to be reasonable. That standard raises the bar for any ERISA challenge considerably. A procedurally defective review process, including one where the reviewer lacked the qualifications to assess the clinical question, can support a challenge if the administrative record documents the deficiency clearly. That record requires the same documentation discipline as the peer-to-peer framework covered in the previous article: reviewer name, stated specialty, date, and a factual account of what the call established.
For most providers, ERISA Section 502(a) is a last resort on high-dollar cases with a well-documented record, not a systematic denial management strategy.
The Contract Language Alternative
Provider contracts with large employer plans and third-party administrators rarely include utilization review standards. They can and should.
A contractual requirement that adverse determinations for specialty services be reviewed by a physician with active board certification in the same or related specialty may survive ERISA preemption where the obligation is enforceable as an independent contractual duty rather than a restatement of plan terms. The Fifth Circuit’s decision in Lone Star OB/GYN Associates v. Aetna Health Inc., 579 F.3d 525 (5th Cir. 2009) established that claims implicating the terms of a provider agreement, rather than the right to payment under plan terms, are not preempted. A negotiated reviewer-qualification standard fits that framework because the duty arises from the contract between the parties, not from the ERISA plan document. Enforcement runs through the contract, not the state statute.
The clause does not need to be elaborate. It should specify that adverse determinations for services within a defined specialty scope be reviewed by a physician with active board certification in the same specialty or subspecialty as the ordering physician, and that the provider may request documentation of reviewer qualifications for any adverse determination within a defined timeframe. That documentation right converts what is currently an informal peer-to-peer question into an enforceable obligation. Contract counsel familiar with ERISA and provider contracting should review any proposed language before submission.
Who Has Leverage and When
Most specialty practices underestimate their negotiating position. Leverage exists when losing a provider group creates a network adequacy problem for the payer. A multi-site oncology practice, a regional radiation therapy group, or a specialty pharmacy in a rural market often carries more weight than its billing volume suggests, because the payer’s alternative to keeping that group in network is explaining a coverage gap to its employer clients.
Practices that have documented a pattern of peer-to-peer reviews where the reviewer’s specialty did not match the clinical question enter contract negotiations with specific evidence rather than general dissatisfaction. PE-backed platforms negotiating master agreements with large commercial payers are the most straightforward case for pursuing this language in the next contract cycle.
When Neither Option Applies
Independent specialty practices in competitive urban markets often face both limited contract leverage and thin or inapplicable state law coverage. For those organizations, the systematic appeal workflow is the primary tool for recovering denied revenue.
Filing every appeal by default, building documentation that addresses the payer’s published clinical criteria rather than a general clinical narrative, and using payer-specific templates constructed from the criteria in the payer’s own policy documents will recover more revenue than any legal or contractual strategy available to a practice in that position. That operational infrastructure does not depend on market position, plan type, or applicable state law.
The Recoverable Revenue Across All Five Parts
This series started with a number: 80.7% of prior authorization denials that were actually appealed were overturned, and only 11.5% were ever appealed. That gap reflects a system in which the administrative cost of appealing falls on providers, payers issue denials at scale knowing most will go unchallenged, and federal preemption removes state law protections for the majority of commercially insured patients.
Operational workflow, state legal standards, and contract language each address a different layer of that system. The practices recovering the most from their denial portfolios have built responses at more than one layer. Start with the data already sitting in your aging report, build the appeal workflow that files everything, and deploy the legal and contractual tools your market and plan mix actually support.
The appeal you did not file is the most expensive decision in your denial management operation.